ABCL · AbCellera Biologics Inc. Common Shares
View on chartInsiders & Stakes
| Thermopylae Holdings Ltd. 10% Owner | ▲ Buy | Open Market | 56,134,097 Shares held | 2/27/2026 | View profile |
| Veronique Lecault Chief Operating Officer | ▲ Buy | Option Exercise | 2,123,456 Shares held | 6/21/2024 | View profile |
| Michael R. Hayden Director | ▲ Buy | Open Market | 1,373,397 Shares held | 8/24/2026 | View profile |
| Carl L. G. Hansen Chief Executive Officer | ▲ Buy | Option Exercise | 898,000 Shares held | 11/25/2024 | View profile |
| Falconer Ester Chief Technology Officer | ▲ Buy | Option Exercise | 875,000 Shares held | 9/1/2021 | View profile |
| Andrew Booth Chief Financial Officer | ▲ Buy | Open Market | 482,800 Shares held | 8/14/2026 | View profile |
| John S. Montalbano Director | ▲ Buy | Open Market | 251,000 Shares held | 8/18/2026 | View profile |
| HAMER JOHN Director | ▼ Sell | Open Market | 128,862 Shares held | 9/1/2021 | View profile |
| Andrew Lo Director | ▲ Buy | Open Market | 86,938 Shares held | 12/3/2021 | View profile |
Transaction History
| Michael R. Hayden | ▲ Buy | Open Market | 53,613 | $570K | 8/24/2026 |
| John S. Montalbano | ▲ Buy | Open Market | 10,000 | $110K | 8/18/2026 |
| Andrew Booth | ▲ Buy | Open Market | 37,200 | $384K | 8/14/2026 |
| Michael R. Hayden | ▲ Buy | Open Market | 46,387 | $481K | 8/12/2026 |
| Michael R. Hayden | ▼ Sell | Gift | 50,000 | $0 | 8/11/2026 |
| Andrew Booth | ▲ Buy | Option Exercise | 250,000 | $48K | 6/3/2026 |
| John S. Montalbano | ▲ Buy | Open Market | 20,000 | $95K | 5/14/2026 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 38,000 | $131K | 2/27/2026 |
| Andrew Booth | ▲ Buy | Open Market | 42,600 | $146K | 2/27/2026 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 177,457 | $580K | 2/26/2026 |
| Thermopylae Holdings Ltd. | ▼ Sell | Gift | 225,000 | $0 | 12/18/2025 |
| John S. Montalbano | ▲ Buy | Open Market | 50,000 | $178K | 11/26/2025 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 343,631 | $742K | 3/11/2025 |
| John S. Montalbano | ▲ Buy | Open Market | 25,000 | $57K | 3/10/2025 |
| John S. Montalbano | ▲ Buy | Open Market | 60,000 | $141K | 3/6/2025 |
| Thermopylae Holdings Ltd. | ▼ Sell | Gift | 286,000 | $0 | 12/4/2024 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 11/25/2024 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 9/20/2024 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 283,516 | $740K | 8/29/2024 |
| Veronique Lecault | ▲ Buy | Option Exercise | 83,334 | $16K | 6/21/2024 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 5/31/2024 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 2/26/2024 |
| Thermopylae Holdings Ltd. | ▼ Sell | Gift | 210,000 | $0 | 12/19/2023 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 11/23/2023 |
| John S. Montalbano | ▲ Buy | Open Market | 10,000 | $45K | 11/8/2023 |
| John S. Montalbano | ▲ Buy | Open Market | 20,000 | $93K | 11/6/2023 |
| Michael R. Hayden | ▲ Buy | Open Market | 20,000 | $98K | 9/22/2023 |
| Veronique Lecault | ▲ Buy | Open Market | 20,000 | $104K | 9/12/2023 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 8/24/2023 |
| Michael R. Hayden | ▲ Buy | Open Market | 30,000 | $177K | 8/8/2023 |
| Andrew Booth | ▲ Buy | Open Market | 14,500 | $99K | 5/26/2023 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 153,000 | $998K | 5/26/2023 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 5/26/2023 |
| Veronique Lecault | ▲ Buy | Option Exercise | 250,000 | $48K | 5/5/2023 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 2/22/2023 |
| Andrew Booth | ▲ Buy | Option Exercise | 50,000 | $10K | 12/20/2022 |
| Andrew Booth | ▼ Sell | Gift | 50,000 | $0 | 12/20/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 85,102 | $859K | 12/16/2022 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 11/18/2022 |
| Thermopylae Holdings Ltd. | ▼ Sell | Gift | 70,000 | $0 | 10/31/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 200,000 | $2.3M | 8/19/2022 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 8/18/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 9,173 | $74K | 6/14/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 54,915 | $441K | 6/13/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 64,545 | $484K | 6/6/2022 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 5/18/2022 |
| Veronique Lecault | ▲ Buy | Open Market | 200,000 | $1.3M | 5/16/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 300,000 | $2.2M | 5/13/2022 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 1,408,468 | $9.0M | 5/12/2022 |
| Andrew Booth | ▲ Buy | Open Market | 85,000 | $492K | 5/12/2022 |
| John S. Montalbano | ▲ Buy | Open Market | 10,000 | $85K | 3/4/2022 |
| John S. Montalbano | ▲ Buy | Open Market | 20,000 | $181K | 3/1/2022 |
| Veronique Lecault | ▲ Buy | Open Market | 230,789 | $2.0M | 2/28/2022 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 56,125 | $152K | 2/22/2022 |
| Andrew Booth | ▲ Buy | Option Exercise | 500,000 | $160K | 12/10/2021 |
| Veronique Lecault | ▲ Buy | Option Exercise | 250,000 | $48K | 12/8/2021 |
| Andrew Lo | ▲ Buy | Open Market | 86,938 | $1.2M | 12/3/2021 |
| Veronique Lecault | ▲ Buy | Option Exercise | 83,333 | $1.2M | 11/30/2021 |
| Carl L. G. Hansen | ▲ Buy | Option Exercise | 224,500 | $3.4M | 11/18/2021 |
| Andrew Booth | ▲ Buy | Open Market | 14,000 | $205K | 11/11/2021 |
| Thermopylae Holdings Ltd. | ▲ Buy | Open Market | 202,960 | $3.0M | 11/11/2021 |
| Andrew Booth | ▲ Buy | Open Market | 53,500 | $789K | 11/11/2021 |
| Michael R. Hayden | ▲ Buy | Option Exercise | 270,000 | $4.8M | 9/13/2021 |
| HAMER JOHN | ▼ Sell | Open Market | 137,351 | $2.3M | 9/1/2021 |
| Falconer Ester | ▲ Buy | Option Exercise | 875,000 | $14.8M | 9/1/2021 |
| HAMER JOHN | ▼ Sell | Open Market | 162,649 | $2.8M | 8/31/2021 |
| John S. Montalbano | ▲ Buy | Open Market | 6,000 | $103K | 8/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results
UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results. UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.